All In Biotech

Drug Trial Radar · NCT04905914

Study Of ATRN-119 In Patients With Advanced Solid Tumors

A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Jan 9, 2023

Primary completion

Mar 9, 2026

Study completion Mar 9, 2026

Sponsor

Lead sponsor
Aprea TherapeuticsIndustry
Sponsor type
Industry
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • ATRN-119Drug

    ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statisticsTime frame: Day 1 to Day 28

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut

  • University Hospitals, Cleveland Medical Center

    Cleveland, Ohio

  • Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Mary Crowley Cancer Research

    Dallas, Texas

  • NEXT- Oncology Dallas

    Irving, Texas

  • NEXT Oncology- San Antonio

    San Antonio, Texas

  • NEXT Oncology- Virginia

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.